1. Home
  2. ADPT vs SFBS Comparison

ADPT vs SFBS Comparison

Compare ADPT & SFBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

N/A

Current Price

$27.73

Market Cap

4.6B

Sector

Health Care

ML Signal

N/A

Logo ServisFirst Bancshares Inc.

SFBS

ServisFirst Bancshares Inc.

N/A

Current Price

$38.63

Market Cap

4.4B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ADPT
SFBS
Founded
2009
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
4.4B
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
ADPT
SFBS
Price
$27.73
$38.63
Analyst Decision
Strong Buy
Buy
Analyst Count
8
3
Target Price
$33.86
★ $46.00
AVG Volume (30 Days)
★ 2.1M
431.3K
Earning Date
11-04-2026
10-19-2026
Dividend Yield
N/A
★ 1.94%
EPS Growth
★ 63.89
21.63
EPS
N/A
★ 2.34
Revenue
★ $276,976,000.00
N/A
Revenue This Year
$10.85
$20.23
Revenue Next Year
$21.60
$8.48
P/E Ratio
★ N/A
$16.72
Revenue Growth
★ 54.77
N/A
52 Week Low
$12.00
$37.51
52 Week High
$32.21
$92.08

Technical Indicators

Market Signals
Indicator
ADPT
SFBS
Relative Strength Index (RSI) 49.06 32.43
Support Level $24.02 $37.51
Resistance Level $29.92 $43.15
Average True Range (ATR) 1.71 1.11
MACD -0.09 -0.13
Stochastic Oscillator 31.91 0.64

Price Performance

Historical Comparison
ADPT
SFBS

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

About SFBS ServisFirst Bancshares Inc.

Servisfirst Bancshares Inc is a bank holding company whose business is conducted by its wholly owned subsidiary. Through the subsidiary, it offers various banking services to individual and corporate customers in Birmingham, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. Its various products and service offerings include commercial, consumer, and other loans; accepting deposits; providing electronic banking services, such as online and mobile banking, including remote deposit capture; delivering treasury and cash management services; and providing banking services to other financial institutions. The company operates as a single reportable segment, with a majority of its revenue being derived from the business of banking.

Share on Social Networks: